share_log

Processa Pharmaceuticals | DEFA14A: Others

SEC announcement ·  Apr 30 04:40
Summary by Futu AI
Processa Pharmaceuticals, Inc., a company listed in the United States, has filed definitive additional materials with the Securities and Exchange Commission (SEC) as part of its proxy solicitation process. This filing, known as a Schedule 14A, is a requirement under Section 14(a) of the Securities Exchange Act of 1934 for companies seeking to communicate with shareholders in connection with an upcoming shareholder meeting or vote. The materials filed by Processa Pharmaceuticals are not preliminary, confidential, or part of a definitive proxy statement, but rather additional information to be considered by shareholders. The company has indicated that no filing fee is required for this submission.
Processa Pharmaceuticals, Inc., a company listed in the United States, has filed definitive additional materials with the Securities and Exchange Commission (SEC) as part of its proxy solicitation process. This filing, known as a Schedule 14A, is a requirement under Section 14(a) of the Securities Exchange Act of 1934 for companies seeking to communicate with shareholders in connection with an upcoming shareholder meeting or vote. The materials filed by Processa Pharmaceuticals are not preliminary, confidential, or part of a definitive proxy statement, but rather additional information to be considered by shareholders. The company has indicated that no filing fee is required for this submission.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.